EP1171147A4 - Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine - Google Patents
Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietineInfo
- Publication number
- EP1171147A4 EP1171147A4 EP00923344A EP00923344A EP1171147A4 EP 1171147 A4 EP1171147 A4 EP 1171147A4 EP 00923344 A EP00923344 A EP 00923344A EP 00923344 A EP00923344 A EP 00923344A EP 1171147 A4 EP1171147 A4 EP 1171147A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- modulation
- tissue function
- excitable tissue
- peripherally administered
- administered erythropoietin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US290938 | 1989-01-04 | ||
US29093899A | 1999-04-13 | 1999-04-13 | |
US54722000A | 2000-04-11 | 2000-04-11 | |
US547220 | 2000-04-11 | ||
PCT/US2000/010019 WO2000061164A1 (fr) | 1999-04-13 | 2000-04-13 | Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1171147A1 EP1171147A1 (fr) | 2002-01-16 |
EP1171147A4 true EP1171147A4 (fr) | 2003-05-14 |
Family
ID=26966493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00923344A Ceased EP1171147A4 (fr) | 1999-04-13 | 2000-04-13 | Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1171147A4 (fr) |
JP (1) | JP2003520194A (fr) |
KR (2) | KR100883232B1 (fr) |
CN (1) | CN1607957B (fr) |
AU (1) | AU784550B2 (fr) |
BG (1) | BG65353B1 (fr) |
BR (1) | BR0009737A (fr) |
CA (1) | CA2383940A1 (fr) |
CR (1) | CR6501A (fr) |
CZ (1) | CZ20013695A3 (fr) |
EA (1) | EA004766B1 (fr) |
HU (1) | HUP0201598A3 (fr) |
IL (2) | IL145895A0 (fr) |
IS (1) | IS6104A (fr) |
MX (1) | MXPA01010177A (fr) |
NO (1) | NO20014991L (fr) |
NZ (4) | NZ545478A (fr) |
PL (1) | PL352223A1 (fr) |
SK (1) | SK14412001A3 (fr) |
TR (2) | TR200103785T2 (fr) |
WO (1) | WO2000061164A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7304031B2 (en) | 2001-10-29 | 2007-12-04 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
WO2003089468A1 (fr) * | 2002-04-19 | 2003-10-30 | Crucell Holland B.V. | Methodes et moyens de production de proteines avec des modifications post-traductionnelles preetablies |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
AU2001267882A1 (en) | 2000-06-30 | 2002-01-14 | Chugai Seiyaku Kabushiki Kaisha | Preventives and remedies for diseases in association with demyelination |
DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
JP2005501801A (ja) * | 2001-02-02 | 2005-01-20 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療 |
US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
ES2297028T3 (es) | 2001-12-07 | 2008-05-01 | Crucell Holland B.V. | Produccion de virus, aislados virales y vacunas. |
US7335490B2 (en) | 2002-01-09 | 2008-02-26 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
KR20060019501A (ko) * | 2002-07-01 | 2006-03-03 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산 |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
RU2341284C2 (ru) * | 2003-03-27 | 2008-12-20 | Янссен Фармацевтика Нв | Применение эритропоэтина в восстановлении после инсульта |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
ATE414144T1 (de) | 2003-05-09 | 2008-11-15 | Crucell Holland Bv | Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon |
DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
PT2371855E (pt) | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
CN101062407A (zh) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | ***在预防或治疗视网膜损伤中的用途 |
US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有***或血小板生成素活性的化合物治疗呼吸链紊乱 |
WO2009010107A1 (fr) * | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques |
WO2009094172A2 (fr) | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Peptides protecteurs de tissu et analogues peptidiques pour la prévention et le traitement de maladies et de troubles associés à un endommagement tissulaire |
RU2519695C2 (ru) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания |
CN111066727B (zh) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010650A1 (fr) * | 1996-09-11 | 1998-03-19 | East Carolina University | Methode de traitement des lesions endotheliales |
WO2000035475A2 (fr) * | 1998-12-14 | 2000-06-22 | Hannelore Ehrenreich | Methode de traitement des ischemies cerebrales et utilisation de l'erythropoietine ou de derives de l'erythropoietine pour traiter les ischemies cerebrales |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
-
2000
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/ja active Pending
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/xx unknown
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/ko not_active IP Right Cessation
- 2000-04-13 NZ NZ560696A patent/NZ560696A/xx not_active IP Right Cessation
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/es active IP Right Grant
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/ko not_active IP Right Cessation
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/pt not_active Application Discontinuation
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/sk not_active Application Discontinuation
- 2000-04-13 CN CN008087466A patent/CN1607957B/zh not_active Expired - Lifetime
- 2000-04-13 IL IL14589500A patent/IL145895A0/xx unknown
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 CA CA002383940A patent/CA2383940A1/fr not_active Abandoned
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/xx unknown
- 2000-04-13 EA EA200101073A patent/EA004766B1/ru not_active IP Right Cessation
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/fr active IP Right Grant
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/cs unknown
- 2000-04-13 EP EP00923344A patent/EP1171147A4/fr not_active Ceased
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/hu unknown
- 2000-04-13 PL PL00352223A patent/PL352223A1/xx not_active Application Discontinuation
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
-
2001
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-11 IS IS6104A patent/IS6104A/is unknown
- 2001-10-12 NO NO20014991A patent/NO20014991L/no not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/bg unknown
- 2001-11-13 CR CR6501A patent/CR6501A/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010650A1 (fr) * | 1996-09-11 | 1998-03-19 | East Carolina University | Methode de traitement des lesions endotheliales |
WO2000035475A2 (fr) * | 1998-12-14 | 2000-06-22 | Hannelore Ehrenreich | Methode de traitement des ischemies cerebrales et utilisation de l'erythropoietine ou de derives de l'erythropoietine pour traiter les ischemies cerebrales |
Non-Patent Citations (20)
Title |
---|
BELAYEV L ET AL: "Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.", BRAIN RESEARCH 23 MAR 1998 LNKD- PUBMED:9518648, vol. 787, no. 2, 23 March 1998 (1998-03-23), pages 277 - 285, ISSN: 0006-8993 * |
BERNAUDIN M ET AL: "A POTENTIAL ROLE FOR ERYTHROPOIETIN IN FOCAL PERMANENT CEREBRAL ISCHEMIA IN MICE", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, RAVEN PRESS, LTD., NEW YORK, NY, US, no. 19, 1999, pages 643 - 651, XP002945970, ISSN: 0271-678X * |
CAMPANA-WM ET AL.: "Identification of a neurotrophic sequence in erythropoietin", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 1, no. 1, 1998, pages 235 - 241, XP001064780 * |
CENGIZ K ET AL: "Does erythropoietin cause epilepsy.", NEPHRON 1996 LNKD- PUBMED:8773367, vol. 73, no. 2, 1996, pages 320 - 321, ISSN: 0028-2766 * |
FRIDEN P M: "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 46, no. 1-2, 5 May 1997 (1997-05-05), pages 117 - 128, XP004096317, ISSN: 0168-3659 * |
HENGEMIHLE J M ET AL: "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice.", PHYSIOLOGY & BEHAVIOR JAN 1996 LNKD- PUBMED:8848475, vol. 59, no. 1, January 1996 (1996-01-01), pages 153 - 156, ISSN: 0031-9384 * |
KANG Y-S ET AL: "PHARMACOKINETICS AND SATURABLE BLOOD-BRAIN BARRIER TRANSPORT OF BIOTIN BOUND TO A CONJUGATE OF AVIDIN AND A MONOCLONAL ANTIBODY TO THE TRANSFERRIN RECEPTOR", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 22, no. 1, 1994, pages 99 - 105, XP002933514, ISSN: 0090-9556 * |
MARTI H H ET AL: "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 51, no. 2, February 1997 (1997-02-01), pages 416 - 418, XP001064793, ISSN: 0085-2538 * |
MIELKE J G ET AL: "Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction.", NEUROSCIENCE LETTERS 23 MAY 1997 LNKD- PUBMED:9185677, vol. 227, no. 3, 23 May 1997 (1997-05-23), pages 169 - 172, ISSN: 0304-3940 * |
MINNERUP-J ET AL.: "EPO for stroke therapy - Is there a future for furtherclinical development?", EXPERIMENTAL & TRANSLATIONAL STROKE MEDICINE, vol. 2, no. 10, DOI: 10.1186/2040-7378-2-10 * |
PAN W ET AL: "Differential permeability of the BBB in acute EAE: enhanced transport of TNT-alpha.", THE AMERICAN JOURNAL OF PHYSIOLOGY OCT 1996 LNKD- PUBMED:8897850, vol. 271, no. 4 Pt 1, October 1996 (1996-10-01), pages E636 - E642, ISSN: 0002-9513 * |
PARDRIDGE W M: "CNS DRUG DESIGN BASED ON PRINCIPLES OF BLOOD-BRAIN BARRIER TRANSPORT", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 70, no. 5, May 1998 (1998-05-01), pages 1782 - 1792, XP000885629, ISSN: 0022-3042 * |
S. PARK, P. SINKO: "Characterization of Biotin Transport across the Blood-Brain Barrier in Mice and Correlation with In Vitro Data", THE AAPS JOURNAL, vol. 6, no. S1, 2004, Retrieved from the Internet <URL:http://www.aapsj.org/abstracts/AM_2004/AAPS2004-002913.PDF> * |
SAKANAKA M ET AL: "In vivo evidence that erythropoietin protects neurons from ischemic damage", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, April 1998 (1998-04-01), pages 4635 - 4640, XP002142085, ISSN: 0027-8424 * |
See also references of WO0061164A1 * |
SHI F ET AL: "Biotin uptake and transport across bovine brain microvessel endothelial cell monolayers.", PHARMACEUTICAL RESEARCH FEB 1993 LNKD- PUBMED:8456078, vol. 10, no. 2, February 1993 (1993-02-01), pages 282 - 288, ISSN: 0724-8741 * |
SØLLING-C ET AL.: "Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia.", ACTA ANAESTHESIOL SCAND - PUBLICATON AHEAD OF PRINT, 22 February 2011 (2011-02-22), DOI: 10.1111/J.1399-6576.2011.02396.X. * |
SQUADRITO F ET AL: "Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.", BRITISH JOURNAL OF PHARMACOLOGY MAY 1999 LNKD- PUBMED:10385249, vol. 127, no. 2, 1 January 1999 (1999-01-01) - May 1999 (1999-05-01), pages 482 - 488, ISSN: 0007-1188 * |
WHALEN M J ET AL: "Blood-brain barrier permeability, neutrophil accumulation and vascular adhesion molecule expression after controlled cortical impact in rats: a preliminary study.", ACTA NEUROCHIRURGICA. SUPPLEMENT 1998 LNKD- PUBMED:9779187, vol. 71, 1998, pages 212 - 214, ISSN: 0065-1419 * |
ZHOU QING-HUI ET AL: "Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.", MOLECULAR PHARMACEUTICS 6 DEC 2010 LNKD- PUBMED:20860349, vol. 7, no. 6, 6 December 2010 (2010-12-06), pages 2148 - 2155, ISSN: 1543-8392 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145895A0 (en) | Modulation of excitable tissue function by peripherally administered erythropoietin | |
GB2357774B (en) | Biioabsorbable cyanoacrylate tissue adhesives | |
AU2560099A (en) | Single-use syringe | |
AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
PL351261A1 (en) | Derivatives of indigoid bisindoles | |
AU7362400A (en) | Occlusion of tubular anatomical structures by energy application | |
HK1043369B (zh) | 調製活細胞核接受體PPARγ活動的化合物 | |
AU2492000A (en) | Implantable neuro-stimulator | |
AU6506698A (en) | Tissue implant | |
PL350854A1 (en) | Intermittent substitutive hormonoal therapy with low doswe of oestrogen | |
ZA200107122B (en) | Treatment of acne using lipoic acid. | |
GB0001140D0 (en) | Microgradient intensity modulating multi-leaf collimator r | |
AU7960800A (en) | X-ray generator of open type | |
AU6115400A (en) | Antisense modulation of mekk5 expression | |
AU7876900A (en) | Antisense modulation of fra-1 expression | |
AU3766700A (en) | Human tumor necrosis factor receptor-like 2 | |
AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
AU6092900A (en) | Animals comprising human hepatocellular tissue | |
AU1878201A (en) | Composition for the treatment of damaged tissue | |
AU2410600A (en) | Antisense modulation of g-alpha-i3 expression | |
AU2501200A (en) | Human peptidases | |
AU1921100A (en) | Antisense modulation of smad4 expression | |
AU5394300A (en) | Tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030328 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 38/18 K Ipc: 7A 61K 31:00 K Ipc: 7A 61K 38:00 J Ipc: 7A 61P 37/00 B Ipc: 7A 61K 38/18 J Ipc: 7A 61K 47/48 B Ipc: 7A 61K 38/18 B Ipc: 7C 07K 14/00 B Ipc: 7A 61K 38/00 A Ipc: 7A 61P 27/00 B Ipc: 7A 61P 25/00 B |
|
17Q | First examination report despatched |
Effective date: 20040319 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20111014 |